NetworkNewsBreaks – Mydecine Innovations Group (
Post# of 160
(Total Views: 186)
Posted On: 12/30/2021 3:14:30 PM
NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed to treat addiction, post-traumatic stress disorder (“PTSD”) and other mental health conditions. “Mydecine recently released its third-quarter 2021 update and a noteworthy announcement for the 2021 calendar year. It offers a glimpse into achievements to date, and what stakeholders can anticipate in the last quarter of the 2021 financial year and for the 2022 calendar year,” reads a recent article. “Most notably, Mydecine filed a patent application for its MYCO-003 drug candidate to treat PTSD and anxiety. It also filed a new patent for MDMA-like compounds, as well as a technology patent for the creation of formulations that use nano-emulsion technologies to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. . . These and other patent applications are helping to expand Mydecine’s robust portfolio of novel compounds while also increasing value to shareholders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed to treat addiction, post-traumatic stress disorder (“PTSD”) and other mental health conditions. “Mydecine recently released its third-quarter 2021 update and a noteworthy announcement for the 2021 calendar year. It offers a glimpse into achievements to date, and what stakeholders can anticipate in the last quarter of the 2021 financial year and for the 2022 calendar year,” reads a recent article. “Most notably, Mydecine filed a patent application for its MYCO-003 drug candidate to treat PTSD and anxiety. It also filed a new patent for MDMA-like compounds, as well as a technology patent for the creation of formulations that use nano-emulsion technologies to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. . . These and other patent applications are helping to expand Mydecine’s robust portfolio of novel compounds while also increasing value to shareholders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)